You are here: Industry Insights > KAF156

News List

Europe-Africa partnership spearheads development of next-generation antimalarial drug europeanpharmaceuticalreview
April 19, 2019
The grant will support African trials of a novel antimalarial combination comprising KAF156 (ganaplacide) and lumefantrine in a new once-daily formulation…
Novartis, Medicines for Malaria Venture launch patient trial for KAF156 pharmaasia
August 31, 2017
Compound has potential to be a game-changer in malaria elimination, rapidly clearing malaria infection and blocking parasite transmission.
Venture launched for a novel compound against malaria europeanpharmaceuticalreview
August 22, 2017
A patient trial for KAF156, a next-generation antimalarial compound with the potential to treat drug-resistant strains of the malaria parasite has been launched…
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156 biospectrumasia
August 22, 2017
Novartis and Medicines for Malaria Venture launch patient trial in Africa for KAF156. The first trial center is operational in Mali and will be followed by sixteen additional centers across a total of nine countries in Africa and Asia over the next few mo
Novartis and MMV launches patient trial in Africa for KAF156 expressbpd
August 22, 2017
KAF156 is first compound from the imidazolopiperazines, a novel class of antimalarials, to enter phase IIb combination studies